The three most well known impotence drugs of course are; Viagra, Cialis and Levitra. But there is a new comer to the block called Uprima (apomorphine hydrochloride) and it is an incredible new approach to the treatment.

It is being touted as the first new type of drug for impotence. The top three drugs are all known as PDE-5 inhibitors that work by relaxing the smooth muscles and blood vessels of the penis. Thus the blood flow can rush in and an erection can be obtained.

Now Uprima on the other hand stimulates a small gland in the brain called the hypothalamus to produce a chemical known as dopamine. This chemical is thought to have somewhat part of the responsibility for initiating an erection.

If we were to look at the end results of the four drugs, we would see that they are the same, however Uprima has some major differences from the other three drugs levitra generique avis.

The first thing you would notice of Uprima is that it is taken not as a pill but sublingually, which means you place it under your tongue and let it dissolve. This means that it works swiftly because it goes through the tongues tissues directly in the bloodstream. What that means is it does not go into the stomach where stomach juices break it down so it keeps its potency.

What all this means is that the new Uprima is lightening fast and you can feel the results within five minutes which is almost four times faster than the blue pill of Viagra. Another benefit is that you can take Uprima with meals.

So I am going to slip in the bad news right here and that is: Uprima is not available in the United States and though they say they have no plans, if it is as good as they say it is. I can not imagine it not being here in the near future.

The most common side effects noted are: nausea, dizziness and headaches. They are mild and short lived.

So that’s the scoop on the new drug Uprima, let us just hope it comes to the United States and helps our men out here.

News Reporter

Leave a Reply

Your email address will not be published. Required fields are marked *